Financial Insights Inc. Makes New $267,000 Investment in DexCom, Inc. $DXCM

Financial Insights Inc. purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the second quarter, Holdings Channel.com reports. The fund purchased 3,057 shares of the medical device company’s stock, valued at approximately $267,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Horizon Investments LLC raised its position in shares of DexCom by 2.2% during the 1st quarter. Horizon Investments LLC now owns 5,608 shares of the medical device company’s stock worth $383,000 after buying an additional 123 shares in the last quarter. Wedbush Securities Inc. raised its position in shares of DexCom by 1.2% during the 1st quarter. Wedbush Securities Inc. now owns 13,168 shares of the medical device company’s stock worth $899,000 after buying an additional 157 shares in the last quarter. Argonautica Private Wealth Management Inc. raised its position in shares of DexCom by 3.2% during the 1st quarter. Argonautica Private Wealth Management Inc. now owns 5,958 shares of the medical device company’s stock worth $407,000 after buying an additional 182 shares in the last quarter. Meiji Yasuda Asset Management Co Ltd. raised its position in shares of DexCom by 3.2% during the 1st quarter. Meiji Yasuda Asset Management Co Ltd. now owns 6,019 shares of the medical device company’s stock worth $411,000 after buying an additional 187 shares in the last quarter. Finally, Integrated Wealth Concepts LLC raised its position in shares of DexCom by 6.3% during the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after buying an additional 196 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

DexCom Stock Performance

DXCM stock opened at $67.05 on Friday. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $26.29 billion, a price-to-earnings ratio of 46.56, a P/E/G ratio of 1.41 and a beta of 1.47. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $93.25. The firm has a 50 day moving average of $76.31 and a two-hundred day moving average of $77.91.

DexCom (NASDAQ:DXCM) last posted its earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, topping the consensus estimate of $0.45 by $0.03. The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The company’s revenue for the quarter was up 15.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Activity

In other news, EVP Sadie Stern sold 1,466 shares of the business’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $80.00, for a total value of $117,280.00. Following the completion of the sale, the executive vice president directly owned 105,223 shares in the company, valued at approximately $8,417,840. The trade was a 1.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Mark G. Foletta sold 2,750 shares of the business’s stock in a transaction on Friday, August 15th. The stock was sold at an average price of $81.06, for a total transaction of $222,915.00. Following the completion of the sale, the director owned 51,121 shares of the company’s stock, valued at $4,143,868.26. The trade was a 5.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 6,849 shares of company stock valued at $564,733 over the last three months. Corporate insiders own 0.32% of the company’s stock.

Wall Street Analysts Forecast Growth

DXCM has been the topic of a number of recent analyst reports. William Blair upgraded shares of DexCom to a “strong-buy” rating in a research report on Thursday, July 31st. UBS Group boosted their target price on shares of DexCom from $105.00 to $106.00 and gave the stock a “buy” rating in a report on Thursday, July 31st. Robert W. Baird dropped their target price on shares of DexCom from $112.00 to $90.00 and set an “outperform” rating on the stock in a report on Friday, September 26th. Oppenheimer downgraded shares of DexCom from an “outperform” rating to a “market perform” rating in a report on Monday, September 8th. Finally, Wall Street Zen downgraded shares of DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, August 10th. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $98.32.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.